Achilles Therapeutics(us:ACHL)
0.9812
+0.01%
Updated on 2024-12-23
Open:0.9900
Close:0.9812
High:0.9900
Low:0.9701
Pre Close:0.9811
Volume:25345.00
Amount:24862.65
Turnover:0.06%
Shares:41.10M
MarketCap:40.33M
About Achilles Therapeutics Company
Achilles Therapeutics Plc is a biopharmaceutical company engaged in developing transformative precision T-cell therapies to treat multiple types of solid tumors. It focuses on researching, developing and commercializing potentially novel cancer immunotherapies targeting clonal neoantigens. The company was founded by Karl Peggs, Sergio Quezada, Mark Lowdell and Charles Swanton in November 2020 and is headquartered in London, the United Kingdom.
Company Name: Achilles Therapeutics
Company Address: 245 Hammersmith Road
Employees: 215
Fiscar Year: 12-31
IPO Date: 2021-03-31
Website: http://www.achillestx.com
CIK: 1830749
View all SEC Filings
About
Achilles Therapeutics Plc is a biopharmaceutical company engaged in developing transformative precision T-cell therapies to treat multiple types of solid tumors. It focuses on researching, developing and commercializing potentially novel cancer immunotherapies targeting clonal neoantigens. The company was founded by Karl Peggs, Sergio Quezada, Mark Lowdell and Charles Swanton in November 2020 and is headquartered in London, the United Kingdom.
Address:245 Hammersmith Road
Website:http://www.achillestx.com
Market Movers